A baseline structure inventory with critical attribution for the US and its territories.

Leveraging high performance computing, remote sensing, geographic data science, machine learning, and computer vision, Oak Ridge National Laboratory has partnered with Federal Emergency Management Agency (FEMA) to build a baseline structure inventory covering the US and its territories to support disaster preparedness, response, and recovery. The dataset contains more than 125 million structures with critical attribution, and is ready to be used by federal agencies, local government and first responders to accelerate on-the-ground response to disasters, further identify vulnerable areas, and develop strategies to enhance the resilience of critical structures and communities. Data can be freely and openly accessed through Figshare data repository, ESRI's Living Atlas or FEMA's Geodata platform.

Impact of Type II LRRK2 inhibitors on signaling and mitophagy.

Much effort has been devoted to the development of selective inhibitors of the LRRK2 as a potential treatment for LRRK2 driven Parkinson's disease. In this study, we first compare the properties of Type I (GSK3357679A and MLi-2) and Type II (GZD-824, Rebastinib and Ponatinib) kinase inhibitors that bind to the closed or open conformations of the LRRK2 kinase domain, respectively. We show that Type I and Type II inhibitors suppress phosphorylation of Rab10 and Rab12, key physiological substrates of LRRK2 and also promote mitophagy, a process suppressed by LRRK2.

Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice.

Parkinson's disease (PD) is a major and progressive neurodegenerative disorder, yet the biological mechanisms involved in its aetiology are poorly understood. Evidence links this disorder with mitochondrial dysfunction and/or impaired lysosomal degradation - key features of the autophagy of mitochondria, known as mitophagy. Here, we investigated the role of LRRK2, a protein kinase frequently mutated in PD, in this process in vivo.

Risk of adverse coronavirus disease 2019 outcomes for people living with HIV.

Objective: To assess whether people living with HIV (PLWH) are at increased risk of coronavirus disease 2019 (COVID-19) mortality or adverse outcomes, and whether antiretroviral therapy (ART) influences this risk.

Design: Rapid review with meta-analysis and narrative synthesis.

Methods: We searched databases including Embase, Medline, medRxiv and Google Scholar up to 26 August 2020 for studies describing COVID-19 outcomes in PLWH and conducted a meta-analysis of higher quality studies.